NCT04679129View on ClinicalTrials.gov

Study to Evaluate Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ASC42 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

November 30, 2020

Primary Completion Date

May 3, 2021

Study Completion Date

June 3, 2021

Conditions
Healthy
Interventions
DRUG

ASC42

Oral tablets

DRUG

Placebo

Oral tablets

Trial Locations (1)

78209

ICON early Phase Services LLC, San Antonio

Sponsors
All Listed Sponsors
lead

Gannex Pharma Co., Ltd.

INDUSTRY